GENNEX

Gennex Laboratories financials

Market cap
₹231 Cr

Quarterly results

Q1 FY27: revenue up 16.6%, net profit down 6.8% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue33 40 40 34 39 +18%43 +7%61 +51%40 +17%
EBITDA7 7 2 5 8 +1%9 +20%6 +192%4 −14%
Net profit5 5 3 5 6 +2%6 +19%4 +45%5 −7%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −3.1% 1Y

₹8.0₹10.0₹12.0₹14.0₹16.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹11.45 on 10 Sept 2025 → ₹11.1. High ₹17.02 (28 Oct 2025), low ₹7.13 (30 Mar 2026).

Financials, as filed

Revenue grew 39.2% a year over 2 years, FY24 to FY26. Operating margin narrowed to 15.3%.

Year endingFY24FY25FY26
Revenue₹92 Cr₹142 Cr₹177 Cr
Operating profit₹22 Cr₹21 Cr₹27 Cr
Operating margin23.9%14.7%15.3%
Interest₹3 Cr₹3 Cr₹4 Cr
Depreciation₹2 Cr₹3 Cr₹3 Cr
Net profit₹13 Cr₹18 Cr₹21 Cr
Net margin14.4%12.8%11.8%
Cash from operations₹-47 Cr₹-11 Cr₹-64 Cr
Free cash flow₹-31 Cr₹-20 Cr₹-76 Cr
ROCE14.0%13.0%11.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹13 Cr₹13 Cr₹18 Cr₹23 Cr₹24 Cr₹24 Cr
Reserves₹27 Cr₹31 Cr₹62 Cr₹148 Cr₹189 Cr₹198 Cr
Borrowings₹7 Cr₹10 Cr₹1 Cr₹6 Cr₹88 Cr₹79 Cr
Other liabilities₹12 Cr₹14 Cr₹51 Cr₹54 Cr₹55 Cr₹47 Cr
Total liabilities₹59 Cr₹68 Cr₹132 Cr₹230 Cr₹357 Cr₹349 Cr
Fixed assets₹14 Cr₹14 Cr₹74 Cr₹56 Cr₹76 Cr₹61 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹2 Cr₹0 Cr₹13 Cr
Investments₹7 Cr₹7 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹38 Cr₹48 Cr₹59 Cr₹172 Cr₹281 Cr₹275 Cr
Total assets₹59 Cr₹68 Cr₹132 Cr₹230 Cr₹357 Cr₹349 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters added +3.81 pp while the public trimmed −3.79 pp. The shareholder count shrank 9% to 82,886.

Promoters
23.6%
Public
76.4%

Since Jun 2025

  • Promoters +3.81 pp
  • Public −3.79 pp

How it drifted, 12 quarters

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 23.6%, Public 76.4%.Dec '23: Promoters 23.6%, Public 76.4%.Mar '24: Promoters 18.4%, Public 81.6%.Jun '24: Promoters 18.4%, Public 81.6%.Sep '24: Promoters 18.4%, Public 81.6%.Dec '24: Promoters 18.4%, Public 81.6%.Mar '25: Promoters 18.4%, Public 81.6%.Jun '25: Promoters 19.8%, Public 80.2%.Sep '25: Promoters 23.6%, Public 76.4%.Dec '25: Promoters 23.6%, Public 76.4%.Mar '26: Promoters 23.6%, Public 76.4%.Jun '26: Promoters 23.6%, Public 76.4%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Gennex Laboratories Ltd above SEBI's 1% disclosure line, and what changed since Mar 2026.

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.